McClay E F, Jones J A, Winski P J, Albright K D, Christen R D, Howell S B
Department of Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston 29425, USA.
Cancer Res. 1996 Sep 1;56(17):3993-7.
The cytotoxic effect of tamoxifen (TAM) was investigated in the T-289 melanoma cell line, as well as the 289 DDP3 cisplatin (DDP)-resistant and the 289 TAM6 TAM-resistant variant melanoma cell lines to determine the effect of drug resistance on synergy. T-289 melanoma cells were made DDP or TAM resistant through chronic exposure to increasing concentrations of the respective drugs. Whereas DDP resistance could be overcome by increasing the concentration of TAM, the development of TAM resistance completely abolished synergy. TAM resistance was not related to the development of estrogen receptors, decreased TAM uptake, or the increased expression of the mdr-1 gene. TAM did not inhibit the action of Topoisomerase 1; however, TAM did induce apoptosis in the 289 melanoma cells. In contrast, TAM did not induce apoptosis in the TAM-resistant variant 289 TAM6 cells. To our knowledge, these are the first data associating TAM resistance with the inhibition of apoptosis.
研究了他莫昔芬(TAM)对T-289黑色素瘤细胞系以及289 DDP3顺铂(DDP)耐药和289 TAM6 TAM耐药的黑色素瘤细胞系变体的细胞毒性作用,以确定耐药性对协同作用的影响。通过长期暴露于浓度不断增加的相应药物,使T-289黑色素瘤细胞产生DDP或TAM耐药性。虽然增加TAM的浓度可以克服DDP耐药性,但TAM耐药性的产生完全消除了协同作用。TAM耐药性与雌激素受体的产生、TAM摄取减少或mdr-1基因表达增加无关。TAM不抑制拓扑异构酶1的作用;然而,TAM确实诱导289黑色素瘤细胞凋亡。相比之下,TAM不诱导TAM耐药变体289 TAM6细胞凋亡。据我们所知,这些是将TAM耐药性与细胞凋亡抑制相关联的首批数据。